Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Global Antibody Drug Conjugate Market Research Report 2016

Wednesday, November 16, 2016 1:39
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Global Antibody Drug Conjugate Market

DelveInsight’s, “Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016 “report provides the information across the ADCs drug value chain. The Report is focused on the marketed and pipeline scenario of the ADCs. The Report has covered the 184 Antibody-drug conjugates profile which gives core information of the targets, mechanism of action, development partner, Technology partner. Antibody Drug Conjugate has covered the three basic component such as monoclonal antibody used, linker used and cytotoxic drugs.

Try Sample Report @

The Report also provides the assessment of the company’s undergone collaborations for technology and monoclonal antibody and also gives insights over the pre-clinical and clinical data. The Report has also assessed the ADCs on geographical distribution based on the country and region. 

There are 5 drugs in pipeline which is in Phase III stage of development. Major Innovations like Antibody Drug-Conjugate (ADCs) have brought the transformative therapy options to billion of patients worldwide. There are 177 pipeline drugs focusing in oncology area followed by immunology. The report covers detailed information of marketed drugs. Seattle Genetics’s Brentuximab vedotin and Roche’s trastuzumab emtansine are the only ADCs approved which have together made USD 981 millions sales in 2014. At the same time pipeline of ADCs is very rich with 184 ADCs in pipeline. 

Access Complete Report @

Report Highlights: 
• A snapshot of the global Antibody-Drug Conjugate market scenario, market trends & drivers, manacles of Antibody-Drug Conjugate. 
• A review of the marketed Antibody-Drug Conjugate products and marketing status 
• Coverage of global antibody-drug conjugate therapies under development across the globe covering territories 
• Competitive landscape of investigational products for key players and key therapy areas. 
• The Antibody-Drug Conjugate report covers the product description, stage of development, licensors & collaborators, Development partner and Technology information 
• The Report also provides the pre-clinical and clinical outcomes of the therapies 
• The Report has covered the targets and detailed mechanism of action 
• Report has highlighted the licensing opportunities and funding details for therapies 
• The report also gives the information of dormant and discontinued pipeline projects 

Reasons to Buy 
• Complete Market and Pipeline intelligence and complete understanding over therapeutics development for Antibody-Drug Conjugate 
• Devise corrective measures for pipeline projects by understanding Therapy area specific therapies 
• Developing strategic initiatives to support your Antibody-Drug Conjugate development activities. 
• Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business. 
• Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
• Evaluate the marketing and pipeline strategy for antibody-drug conjugate therapies and their funding details. 
• Identifying the upcoming leaders in the Antibody-Drug Conjugate market in the coming years. 

Table of contents:

Report Introduction 
Executive Summary 
Scope of the Report 
Historical Perspective of Antibody-Drug Conjugate 
Design of Antibody-Drug Conjugate 
Different components of Antibody-Drug Conjugate 
Immunocongugate–A distinct class of therapeutics in Oncology 
Advantages of ADC over Traditional Therapies 
Important Hurdles Faced in Development and Commercialization of ADC 
Current scenario of Marketed and Pipeline Antibody-Drug Conjugate 
Antibody-Drug Conjugate Marketed Scenario 
Antibody-Drug Conjugate Pipeline Scenario 
Current Therapy Areas under Research for Antibody-Drug Conjugate Development 
Companies Involved in Antibody-Drug Conjugate Market 
Numerous big pharmaceutical companies are showing interest in ADC market and why? 
Companies with the Technology for Antibody-Drug Conjugate Products Development 
Companies in Collaboration for Technology 
Companies with Monoclonal Antibodies for the Antibody Drug Development 
Companies in Collaboration for Monoclonal Antibodies 
Geographical Distribution of Companies involved in ADC Drugs Development (Drug) 
Geographical Distribution of Companies by Region 
Geographical Distribution of Companies by Country 
Antibody-Drug Conjugate Drugs under Different classes of Linkers 
Marketed Antibody-Drug Conjugates and their Global Impact 
Market Size Assessment of Antibody-Drug Conjugates 
Antibody-Drug Conjugates in Pipeline 
Last Stage Products (Phase III) 
Comparative Analysis 
Mid Stage Products (Phase II) 
Comparative Analysis 
Early Stage Products (Phase I) 
Comparative Analysis 
Pre-clinical stage Products 
Comparative Analysis 
Discovery Products 
Comparative Analysis 
Dormant Products 
Discontinued Products 
Report Purchase Options 
About DelveInsight

List of tables: 
Table 1: Marketed and Pipeline Antibody-Drug Conjugates, 2016 
Table 2: Antibody-Drug Conjugatein Pipeline by Phase, 2016 
Table 3: Therapeutic Areas under Research for Antibody-Drug Conjugate Products, 2016 
Table 4: Number of Companies Targeting Different Therapeutics Areas in Antibody-Drug Conjugate Market Globally, 2016 
Table 5: Number of Companies Targeting Different Therapeutics Areas in Antibody-Drug Conjugate Market Globally, 2016 
Table 6: Number of Companies Technology for Antibody-Drug Conjugates Development, 2016 
Table 7: Number of Companies with Monoclonal Antibodies for Antibody-Drug Conjugates Development, 2016 
Table 8: Number of Companies Monoclonal Antibodies for Antibody-Drug Conjugates Development, 2016 
Table 9: Antibody-Drug Conjugate Global Sales (in million USD), 2016 
Table 10: Adcetris, Global Sales from 2011-2013 (in million USD), 2016 
Table 11: Kadcyla, Global Sales from 2013 (in million USD), 2016 
Table 12: Last Stage Products Phase III, 2016 
Table 13: Mid Stage Products (Phase II), 2016 
Table 14: Early Stage Products (Phase I), 2016 
Table 15: Pre-clinical Stage Products, 2016 
Table 16: Discovery Stage Products, 2016 
Table 17: Dormant Products, 2016 
Table 18: Discontinued Products, 2016 

Buy Report @

For more information or any query mail at

Contact Us:
Norah Trent
+1 646 845 9349 / +44 208 133 9349
Follow on LinkedIn:

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.